Venetoclax/ABT199 (VEN) is a Bcl-2-specific inhibitor, clinically approved for the treatment of chronic lymphocytic leukemia (CLL) and acute myeloid leukemia (AML) [1, 3, 4]. The gene discussed is BCL2; the disease is B-cell chronic lymphocytic leukemia.